Targets › LHR
2 programs from 2 companies in 3 trials: 2 Phase 4, 1 Phase 3; Genitourinary; next expected readout Aug 2027.
Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection. (UniProt, P16070)
Open in Phaseline: the race on LHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fundación Santiago Dexeus Font | rhFSH+rhLH (Pergoveris®) Recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone | FSHR, LHR | Phase 4 | Infertility | Aug 2027 |
| Granata Bio | hMG (human menopausal gonadotropin) Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist | FSHR, LHR | Phase 3 | Infertility (IVF Patients) | Nov 2028 |
Infertility (2) Infertility (IVF Patients) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.